Literature DB >> 12041701

Radiation-induced liver injury showing low intensity on T2-weighted images noted in Budd-Chiari syndrome.

Harushi Mori1, Hiroshi Yoshioka, Kensaku Mori, Tayeb Ahmadi, Toshiyuki Okumura, Yukihisa Saida, Yuji Itai.   

Abstract

PURPOSE: Although it is documented that radiation can cause density or intensity changes on computed tomography or MR imaging in the irradiated hepatic parenchyma, few researchers have reported or understood the MR presentation of changes in hepatic parenchyma following radiotherapy in the patient with Budd-Chiari syndrome. The purpose of this study was to investigate the MR appearance of hepatic radiation injury in Budd-Chiari syndrome and to consider the underlying pathophysiology.
MATERIALS AND METHODS: The MR examinations of two patients with Budd-Chiari syndrome were compared with those of 11 patients without Budd-Chiari syndrome. The two groups, both of which suffered from hepatocellular carcinoma, underwent 50-72 Gy of proton-beam irradiation during a period of 14-43 days. Examinations including T1- and T2-weighted imaging, superparamagnetic iron oxide-enhanced imaging, and dynamic study were performed 3-10 weeks after the end of irradiation.
RESULTS: Radiation-induced hepatic injury was observed as a low-intensity area on T2-weighted images and on delayed phase images of dynamic study in the Budd-Chiari patients, and as iso- or high-intensity areas on both images in the patients without Budd-Chiari syndrome. US-guided needle biopsy from the irradiated area in one patient with Budd-Chiari syndrome revealed mostly necrotic tissue and fibrous tissue.
CONCLUSION: These MR features of hepatic radiation injury in Budd-Chiari syndrome were considered to be due to severe hepatic fibrosis.

Entities:  

Mesh:

Year:  2002        PMID: 12041701

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  1 in total

1.  Huangqi Shengmai Yin Protects against Radiation-Induced Cardiac Fibrosis Injury by Regulating the TGF-β1/Smads and MMPs.

Authors:  Jing Gu; Yongqi Liu; Hongyan Wu; Hailong Li; Kai Liu
Journal:  Evid Based Complement Alternat Med       Date:  2019-05-13       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.